Ізраїль - англійська - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.

Ізраїль - англійська - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.

Ізраїль - англійська - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation

Ізраїль - англійська - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - peppermint oil - oral solution - .5microlitre/1ml

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - peppermint oil - oral solution - .5microlitre/1ml

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - propofol, quantity: 10 mg/ml - injection, emulsion - excipient ingredients: sodium hydroxide; soya oil; disodium edetate; glycerol; water for injections; egg lecithin - diprivan is a short-acting intravenous anaesthetic agent suitable for induction and maintenance of general anaesthesia in adults and in children aged three years and older. diprivan has no analgesic properties. although the safety and efficacy of diprivan in paediatric day surgery have not been demonstrated, it may be a useful agent in this setting and its use should not be precluded. diprivan may also be used in adults for sedation of ventilated patients receiving intensive care. diprivan may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures. indications as at 4 november 2004: induction of general anaesthesia in children and adults. diprivan is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older. maintenance of general anaesthesia in children and adults. diprivan is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older. diprivan may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided. diprivan has no analgesic properties. sedation during intensive care in adults. diprivan may also be used in adults for sedation of ventilated patients receiving intensive care. conscious sedation for surgical and diagnostic procedures in adults. diprivan may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - propofol, quantity: 10 mg/ml - injection, emulsion - excipient ingredients: glycerol; disodium edetate; sodium hydroxide; egg lecithin; soya oil; water for injections - diprivan is a short-acting intravenous anaesthetic agent suitable for induction and maintenance of general anaesthesia in adults and in children aged three years and older. diprivan has no analgesic properties. although the safety and efficacy of diprivan in paediatric day surgery have not been demonstrated, it may be a useful agent in this setting and its use should not be precluded. diprivan may also be used in adults for sedation of ventilated patients receiving intensive care. diprivan may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures. indications as at 4 november 2004: induction of general anaesthesia in children and adults. diprivan is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older. maintenance of general anaesthesia in children and adults. diprivan is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older. diprivan may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided. diprivan has no analgesic properties. sedation during intensive care in adults. diprivan may also be used in adults for sedation of ventilated patients receiving intensive care. conscious sedation for surgical and diagnostic procedures in adults. diprivan may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - propofol, quantity: 10 mg/ml - injection, emulsion - excipient ingredients: egg lecithin; sodium hydroxide; disodium edetate; glycerol; water for injections; soya oil - diprivan is a short-acting intravenous anaesthetic agent suitable for induction and maintenance of general anaesthesia in adults and in children aged three years and older. diprivan has no analgesic properties. although the safety and efficacy of diprivan in paediatric day surgery have not been demonstrated, it may be a useful agent in this setting and its use should not be precluded. diprivan may also be used in adults for sedation of ventilated patients receiving intensive care. diprivan may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures. indications as at 4 november 2004: induction of general anaesthesia in children and adults. diprivan is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older. maintenance of general anaesthesia in children and adults. diprivan is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older. diprivan may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided. diprivan has no analgesic properties. sedation during intensive care in adults. diprivan may also be used in adults for sedation of ventilated patients receiving intensive care. conscious sedation for surgical and diagnostic procedures in adults. diprivan may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - propofol, quantity: 10 mg/ml - injection, emulsion - excipient ingredients: glycerol; soya oil; disodium edetate; egg lecithin; sodium hydroxide; water for injections - diprivan is a short-acting intravenous anaesthetic agent suitable for induction and maintenance of general anaethesia in adults and in children aged three years and older. diprivan has no analgesic properties. although the safety and efficacy of diprivan in paediatric day surgery have not been demonstrated, it may be a useful agent in this setting and its use should not be precluded. diprivan may also be used in adults for sedation of ventilated patients receiving intensive care. diprivan may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures. indications as at 4 november 2004: induction of general anaesthesia in children and adults. diprivan is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older. maintenance of general anaesthesia in children and adults. diprivan is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older. diprivan may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided. diprivan has no analgesic properties. sedation during intensive care in adults. diprivan may also be used in adults for sedation of ventilated patients receiving intensive care. conscious sedation for surgical and diagnostic procedures in adults. diprivan may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.